Separately, Zacks Investment Research lowered Rexahn Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, January 4th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $13.75.
Rexahn Pharmaceuticals (NYSEAMERICAN RNN) opened at $1.65 on Monday. Rexahn Pharmaceuticals has a 52-week low of $1.51 and a 52-week high of $7.10. The company has a market cap of $51.41, a P/E ratio of -1.77 and a beta of -0.35.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3258931/rexahn-pharmaceuticals-rnn-given-a-20-00-price-target-at-hc-wainwright.html.
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.